US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Interim report January-June 2021: Increased net sales of 628% driven by M&A and organic growth of 95% and positive EBITDA in Q2.

Name change to BICO Group AB (publ)  The company changed its name per August 12, 2021, from CELLINK AB (publ) to BICO Group AB (publ). The company’s ticker is BICO and the first trading day with the new ticker was on Monday, August 16, 2021. The company’s ISIN code and Order book ID are unchanged. This is an administrative matter and shareholders do not need to take any action. Second quarter: April-June 2021 · Net sales amounted to MSEK 293.1 (40.2), which corresponds to an increase of 628% (36) compared to the corresponding period previous year, of which 95% (8) was organic

CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows

CYTENA Bioprocess Solutions, a CELLINK company, has launched the S.NEST™, a state-of-the art microbioreactor that maximizes cell growth while monitoring and analyzing cell conditions from start to finish. Well-known for combining innovative bioscience technologies with best-in-class software development, CYTENA Bioprocess Solutions has developed their new microbioreactor to disrupt the field of cell line development (CLD). Microbioreactors have been instrumental in a string of research breakthroughs in CLD for a range of downstream applications, but with the addition of real-time

Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services

Over the last two months, both MatTek and Visikol have been acquired by CELLINK, the world’s leading bioconvergence company. CELLINK is focused on bringing together, the technologies, products, services, and people required to create the future of medicine. Together, MatTek and Visikol bring significant experience with providing researchers best-in-class in vitro models and services for evaluating the safety, efficacy and pharmacokinetics of therapeutics and personal care products. Today, the two companies are announcing that Visikol will now be leveraging the MatTek portfolio of advanced

CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office

CELLINK has been granted a patent for its unique cellulose-based bioink technology enabling bioprinting of multiple cell types for tissue engineering and regenerative medicine applications. The patent protection applies to the European market, one of CELLINK’s most important markets.The granted patent from the European Patent Office shows novelty, inventive step, and industrial applicability. This technology is used in CELLINK’s first universal bioink, CELLINK® Bioink, which has expanded into the CELLINK bioink Series (CELLINK® RGD, CELLINK® FIBRIN, CELLINK® SKIN, CELLINK® BONE and CELLINK®

CELLINKs EpiDerm ™ skin model has been approved by the OECD as a stand-alone in-vitro test method for phototoxicity

MatTek Life Sciences, a subsidiary of CELLINK, today announced the acceptance of the EpiDerm™ Phototoxicity Test as part of Test Guideline No. 498 In vitro Phototoxicity: Reconstructed Human Epidermis Phototoxicity Test Method  by the Organization of Economic Cooperation and Development (OECD). This effort is very much in line with the Group’s goals to reduce and eventually replace animal testing by developing technologies and methods that are more human-

CELLINK has acquired Visikol, a contract research services company focused on advanced imaging, 3D cell culture assays and digital pathology

CELLINK has acquired Visikol Corp., an American contract research services company offering leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharma and biotech companies. CELLINK has acquired all outstanding shares in Visikol for a purchase price of $7.5 million on a cash- and debt-free basis under the assumption that the working capital at closing equals the normalized working capital at closing of which approximately $2.5 million will be paid in 57,911 newly issued shares of series B in CELLINK at a price of SEK 357.60 per share (

CELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of Nanoscribe Holding GmbH ("Nanoscribe"), a market leading and award-winning German company focusing on development of high-precision 3D printers based on Two-Photon Polymerization technology (“2PP”), to acquire all outstanding shares on a cash- and debt-free basis, and under the assumption that the working capital at closing equals the normalized working capital, to a purchase price of €34 million and approximately €16 million in earn-outs, in Nanoscribe (the "Acquisition"). Approximately thirty-five percent

Interim report January-March 2021: High organic growth, strengthened gross margin, and strategic acquisitions

First quarter, 2021 · Net sales amounted to MSEK 129.5 (38.0), which corresponded to an increase of 241% (55) compared to the corresponding period previous year, of which 62% (25) was organic growth. · Operating profit before depreciation (EBITDA) amounted to MSEK -34.9 (-5.7), corresponding to a margin of -26.9% (-14.9). The operating profit during the quarter was affected by acquisition costs totaling MSEK 20.5. · Profit/loss for the period amounted to MSEK -47.8 (-33.5), which generated earnings per share after dilution of SEK -0.90 (-0.80). The result was positively affected

CELLINK and UPM Biomedicals has formed a collaboration for ground-breaking 3D bioprinting developments

CELLINK entered a collaboration with UPM Biomedicals in March which is now running according to plan. The partnership brings together UPM:s expertise for producing non-animal derived, nanocellulose biomaterials with CELLINK’s years of experience in method development for 3D bioprinting, offering new ground-breaking solutions to this growing life sciences market.Advances in 3D printing in the past decade have been outstanding, and the technology is becoming more widely used for various cutting-edge applications. 3D bioprinting is already important in areas such as cancer research, where

Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda

CELLINK invites investors, analysts, shareholders, and media to a digital Capital Markets Day (CMD) on Wednesday May 12, 2021 at 2-5pm (CEST).We are the frontrunners in the evolving life science universe where we together with our customers develop game-changing solutions by combining biology and technology through our agenda for bioconvergence. CELLINK creates the future of medicine by providing technologies, products, and services for our customers to create, understand and master biology. Please join us during our CMD and explore our bioconvergence agenda, get to know our business

CELLINK publishes Annual Report 2019/2020

CELLINK has published Annual Report 2019/2020 for the financial year which covers September 1, 2019 to December 31, 2020. The Annual Report is available on CELLINK’s website: www.cellink.com/investors. The printed version of Annual Report 2019/2020 will be available during calendar week 13.    For more information, please contact:Isabelle Ljunggren, Head of Communications CELLINKPhone: +46 708-30 08 90Email: il@cellink.com This is information that CELLINK is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 16:50 CET

CELLINK has entered into an agreement to acquire MatTek, the global leader in in-vitro technology and alternative drug testing models

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of MatTek Corporation ("MatTek"), an American company focusing on advanced in-vitro technology for clinical and pre-clinical studies offering in-vitro human tissue model innovation, cell isolation and cell culture, to acquire all outstanding shares in MatTek for a purchase price on a cash- and debt-free basis of $68 million (the "Acquisition"). Twenty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash.

Year-end report 19/20: Continued strong organic growth, positive result and strategic investments for the future

Fifth quarter (September – December 2020, 4 months) · Net sales amounted to SEK 239,216 thousand (SEK 50,189 thousand), which corresponds to an increase of 377% (118%) compared to the corresponding period a year earlier, of which 73% (47%) was organic growth. The acquisition of Scienion has since September 1, 2020 contributed with SEK 152,176 thousand in sales. · Operating profit before depreciation (EBITDA) amounted to SEK 40,414 thousand (SEK -15,567 thousand), corresponding to a margin of 16.9% (-31.0%). · Profit for the period amounted to SEK 13,219 thousand (SEK -18,895

Invitation to CELLINK’s earnings call – Year-end Report 2019/2020

On February 25, 08.00 (CET) CELLINK will publish the Year-end Report 2019/2020 and will also arrange an earnings call, 14:00 (CET) the same date. The earnings call will be available afterwards on the company’s website Investor section.Before the start of the conference call the earnings call presentation will be available on the company's website  Investor section. The presentation will be held in English. Date: Thursday, February 25, 2021. 14:00 (CET)For audio: +46 8 502 439 36  Conference ID: 888 731 010#For video:

CELLINK has entered into an agreement to acquire the advanced robotics and diagnostics automation company Ginolis

CELLINK AB (publ) ("CELLINK") has entered into an agreement with the shareholders of Ginolis Oy ("Ginolis"), a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries, to acquire all shares for a purchase price on cash- and debt-free basis of 70M euros (the "Acquisition"). Forty percent of the purchase price will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining purchase price in cash. CELLINK’s Board of Directors will resolve to issue the Consideration Shares in accordance with

There are no items matching the current filter
There are no more items matching the current filter
Back to top